Pharmaxis grants BI option on NASH program PXS4728A; option exercised
For a fee of €1.25mm ($1.33mm), Pharmaxis Ltd. granted Boehringer Ingelheim GMBH an option to license exclusive worldwide rights to its Phase I nonalcoholic steatohepatitis (NASH) candidate PXS4728A, an inhibitor of semicarbazide-sensitive amine oxidase (SSAO; also known as vascular adhesion protein-1 (VAP-1)).
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.